allowing pooling resources force drugs lower prices reduce overall innovation
reducing profit  reduces motive money necessary get drug organization trials
without profit motive  drug companies naturally move away rare complex  yet fatal  diseases affect small percentage people
without ability set price  resources naturally moved almost exclusively benign treatments larger percentage population potential users
